Efficacy and safety of stellate ganglion block in chronic ulcerative colitis

Hong-Ying Zhao, Guo-Tao Yang, Ning-Ning Sun, Yu Kong, Yun-Feng Liu

AIM
To investigate the efficacy and safety of stellate ganglion block for the treatment of patients with chronic ulcerative colitis.

METHODS
A total of 120 randomly selected patients with chronic ulcerative colitis treated in Cangzhou Central Hospital from January 2014 to January 2016 were included in this study. These patients were divided into two groups: control group (n = 30), patients received oral sulfasalazine treatment; experimental group (n = 90), patients received stellate ganglion block treatment. Clinical symptoms and disease activity in these two groups were compared before and after treatment using endoscopy. Blood was collected from patients on day 0, 10, 20 and 30 after treatment. Enzyme-linked...
immunosorbent assay was performed to determine interleukin-8 (IL-8) level. The changes in IL-8 level post-treatment in the two groups were compared using repeated measures analysis of variance.

RESULTS
After treatment, clinical symptoms and disease activity were shown to be alleviated by endoscopy in both the control and experimental groups. However, patients in the control group did not have obvious abdominal pain relief. In addition, the degree of pain relief in the experimental group was statistically better than that in the control group (P < 0.05). Ten days after treatment, IL-8 level was found to be significantly lower in the experimental group than in the control group, and the difference was statistically significant (P < 0.05). In addition, adverse events were significantly higher in the control group than in the experimental group, and the difference was statistically significant (χ² = 33.215, P = 0.000).

CONCLUSION
The application of stellate ganglion block effectively improves treatment efficacy in chronic ulcerative colitis, relieves clinical symptoms in patients, and reduces the level of inflammatory factors. Furthermore, this approach also had a positive impact on the disease to a certain extent.

Key words: Stellate ganglion block; Chronic ulcerative colitis

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: A total of 120 patients with chronic ulcerative colitis were included in this study to examine the efficacy and safety of stellate ganglion block in patients with chronic ulcerative colitis. The results revealed that stellate ganglion block effectively improves the efficacy of chronic ulcerative colitis treatment, relieves clinical symptoms in patients, and reduces the level of inflammatory factors. Furthermore, this technique has fewer adverse reactions, making it safe and reliable.

Zhao HY, Yang GT, Sun NN, Kong Y, Liu YF. Efficacy and safety of stellate ganglion block in chronic ulcerative colitis. World J Gastroenterol 2017; 23(3): 533-539 Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i3/533.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i3.533

INTRODUCTION
Chronic ulcerative colitis is a common disease and has a high incidence. Its main clinical manifestations include abdominal pain, tenesmus and sepsis, and it can decrease the quality of life of patients[16]. Ulcers of the colonic mucosa occur in patients with this disease, which can affect the entire colon and rectum, and can easily induce repeated attacks. Sulfasalazine is a commonly used conventional treatment for chronic ulcerative colitis. However, this treatment has certain limitations such as frequent recurrence and side effects. Hence, there is a need for better treatment options[7-13]. Although the pathogenesis of chronic ulcerative colitis is unclear, a close relationship between the disease and immune dysfunction has been confirmed. Furthermore, the expression of cytokines, particularly interleukin-8 (IL-8), significantly increases during the disease course[14-22]. Stellate ganglion block is a very common clinical block technique that has been used since the beginning of the last century. Studies have shown that stellate ganglion blocks can regulate multiple system functions in the body, and has a good effect on blood pressure, hyperthyroidism, peripheral facial paralysis and other diseases[23-27]. With the current rapid development of medicine, some scientists have found that the stellate ganglion block technique also plays an important role in regulating the immune system[28-32]. Thus, we speculate that stellate ganglion blocks may also have a role in the treatment of chronic ulcerative colitis. Therefore, the main purpose of this study was to examine the efficacy and safety of stellate ganglion block treatment in patients with chronic ulcerative colitis.

MATERIALS AND METHODS

General information
A total of 120 randomly selected patients with chronic ulcerative colitis treated in Cangzhou Central Hospital between January 2014 and January 2016 were included in this study. These patients were divided into two groups: control group (n = 30) and experimental group (n = 90). The control group comprised 19 male patients (63.3%) and 11 female patients (36.7%) aged between 39 and 56 years, with a mean age of 47.1 ± 5.9 years. Furthermore, the disease course ranged from two months to 10 years, with an average of 4.1 ± 1.4 years. The experimental group comprised 54 male patients (60.0%) and 36 female patients (40.0%), aged between 40 and 57 years, with a mean age of 48.2 ± 6.0 years. Furthermore, the disease course ranged from four months to nine years, with an average of 4.3 ± 1.5 years. Patients in the experimental group were not allergic to lidocaine and had no coagulation disorders. This study was approved by the ethics committee of the institution.

Methods
In the control group, patients received four doses of sulfasalazine twice a day orally. In the experimental group, patients received stellate ganglion block treatment once a day for 30 d. The blocking method used was as follows: 10 mL of 1% lidocaine was injected into the sixth cervical vertebrae, and Horner syndrome
was observed in these patients. The stellate ganglion block technique was considered successful when no abnormal situations occurred within 30 min.

**Outcome measures**

**Clinical symptoms and IL-8 level:** Clinical symptoms were observed before and after treatment. Blood was drawn from patients at the beginning of treatment, on the morning of day 0, and on the 10th, 20th, and 30th day after treatment. IL-8 levels were then determined by enzyme-linked immunosorbent assay. Changes in clinical symptoms and related indicators were analyzed and compared in the two groups after treatment.

**Screening colonoscopy:** Colonoscopy lesions were scored before and after treatment using the Rachmilewitz scoring system.

**Statistical analysis**

SPSS 17.0 software was used for statistical analysis. Time to defecation and cytokine expression level were determined. The two treatment groups were compared using the t-test. The number of cases of abdominal pain, pus and tenesmus were used as enumeration data. Comparisons in these two groups were evaluated using Pearson’s $\chi^2$ test.

**RESULTS**

**Comparison of related indices in the two groups before treatment**

The differences in the number of patients with blood and pus and tenesmus accompanied by abdominal pain and the average time to defecation before treatment in the control and experimental groups were not statistically significant ($P > 0.05$). In addition, the difference in IL-8 expression level between these two groups were not statistically significant ($P > 0.05$), as shown in Table 1.

**Remission of clinical symptoms in the two groups after treatment**

Clinical symptoms in patients in the control and experimental groups were alleviated after treatment. However, abdominal pain was not significantly relieved in patients in the control group. Furthermore, remission in the experimental group was better than that in the control group, and the difference was statistically significant ($P < 0.05$; Table 2).

**Comparison of IL-8 expression levels in patients after treatment**

In this study, IL-8 expression level was significantly lower in the experimental group than in the control group; and the difference was statistically significant ($P < 0.05$). Furthermore, the duration of treatment and IL-8 expression were significantly reduced in the experimental group, and the differences were statistically significant ($P < 0.05$). However, these differences were not significant in the control group. The maximum value of the measured data was reached at day 0 in the control group, while the minimum value was reached during the first 30 d in the experimental group. In addition, no interactions ($F = 2.981, P = 0.139$) between the different time points and group-

---

**Table 1 Clinical symptoms in the control and experimental groups before treatment n (%)**

| Indices (clinical symptoms) | Control group ($n = 30$) | Experimental group ($n = 90$) | $t$/$\chi^2$ | $P$ value |
|----------------------------|--------------------------|-----------------------------|-------------|----------|
| Stomach ache                | 17 (56.67)               | 50 (55.56)                  | 0.025       | 0.874    |
| Time to defecation (x ± s)  | 8.50 ± 1.31              | 8.71 ± 1.40                 | -0.723      | 0.471    |
| Blood and pus               | 10 (33.33)               | 29 (32.22)                  | 0.028       | 0.867    |
| Tenesmus                    | 13 (43.33)               | 38 (42.22)                  | 0.025       | 0.874    |
| Interleukin-8 (ng/L)        | 25.83 ± 3.01             | 24.97 ± 2.98                | 1.366       | 0.175    |

**Table 2 Clinical symptoms of patients in the two groups after treatment n (%)**

| Group                        | Stomach ache | Time to defecation (x ± s ) | Blood and pus | Tenesmus |
|------------------------------|--------------|-----------------------------|---------------|----------|
| Control group Before treatment | 17 (56.67) | 8.50 ± 1.31                | 10 (33.33)   | 13 (43.33) |
| After treatment              | 13 (43.33)  | 2.91 ± 0.97                 | 5 (16.67)    | 7 (23.33) |
| $t$/$\chi^2$ $P$ value       | 3.548        | 18.784                      | 7.401         | 9.000    |
|                              | 0.060        | 0.000                       | 0.007         | 0.003    |
| Experimental group Before treatment | 50 (55.56) | 8.71 ± 1.40                 | 29 (32.22)   | 38 (42.22) |
| After treatment              | 8 (8.89)    | 1.12 ± 0.87                 | 4 (4.44)    | 6 (6.67) |
| $t$/$\chi^2$ $P$ value       | 49.864       | 43.684                      | 25.776       | 34.213   |
|                              | 0.000        | 0.000                       | 0.000        | 0.000    |

* $P < 0.05$ vs the control group.
Colonoscopy scores significantly decreased at 30 d after treatment in both groups. However, these scores decreased more significantly in the experimental group, compared with the control group; and the difference was statistically significant ($P < 0.05$; Figure 2).

**Adverse reactions**

In the control group, 13 patients experienced stomach discomfort, liver and kidney dysfunction, headache, and other adverse reactions. In the experimental group, only seven patients had mild pain in the neck, which disappeared after a few days. The proportion of adverse events was significantly higher in the control group; and the difference was statistically significant ($\chi^2 = 33.215, P = 0.000$; Table 4).

**DISCUSSION**

In recent years, the incidence of chronic ulcerative colitis has gradually increased. This recurrent disease causes serious harm to human health. Sulfasalazine is a commonly used drug for treating chronic ulcerative colitis. However, due to its side effects, better methods of treatment are required. The pathogenesis of chronic ulcerative colitis is complex. However, recent studies have shown that this disease and immune dysfunction are correlated, and that the stellate ganglion block technique plays a very important role in regulating immune function. Therefore, the main aim of this study was to investigate the efficacy and safety of the stellate ganglion block technique in the treatment of chronic ulcerative colitis.

**IL-8 content in patients in the two groups before and after treatment**

Research has shown that the occurrence of chronic ulcerative colitis is accompanied by the formation of immune complexes and cytokines, which is difficult to treat. Of these cytokines, IL-8 can lead to chemotaxis of neutrophils, eosinophils, lymphocytes and other cells, and the release of media that can damage...
Changes in clinical symptoms in the two groups before and after treatment

Abdominal pain, tenesmus and sepsis are the main clinical manifestations of chronic ulcerative colitis, which seriously affect the normal daily life of patients[46]. Sulfasalazine is a commonly used drug for treating chronic ulcerative colitis. However, it has some limitations due to its side effects[10]. Therefore, this study used stellate ganglion block as a new method for treating this disease from the perspective of immunology. Patients were divided in the control group who were treated with conventional sulfasalazine, and the experimental group in which patients were treated with stellate ganglion block.

Pus and tenesmus symptoms were significantly reduced in both groups. The time to defecation was also significantly reduced in both groups, but relief of clinical symptoms was more obvious in the experimental group. Furthermore, colonoscopy scores were significantly decreased in the experimental group compared with the control group. In addition, research has shown that immune function in the human body induces environment stability and defense, as well as other vital functions; and counting and activity improves humoral immunity. Finally, this treatment reduces the production of inflammatory cytokines in vivo in patients with chronic ulcerative colitis, and improves clinical symptoms[46]. Furthermore, studies have shown that the stellate ganglion block technique improves blood circulation by inhibiting the activity of the sympathetic nervous system. This can provide chronic ulcerative colitis patients with immune complexes and induces the rapid clearance of inflammatory cytokines, thereby improving the condition of patients[10].

Adverse reactions

Fewer adverse symptoms were observed following treatment with the stellate ganglion block technique, and the liver, kidney, stomach and other organs were less affected, when compared with the control group. These findings indicate that the stellate ganglion block has good healing power and few side effects, demonstrating that this treatment is safe and reliable.

This study has limitations. The sample size was small. Furthermore, IL-8 levels in patients included into this study were not compared with healthy subjects. Hence, further studies with a larger sample size are needed.

In conclusion, the stellate ganglion block technique is a new method for treating chronic ulcerative colitis. This method can significantly improve clinical symptoms, reduce the production of inflammatory cytokines, has fewer adverse reactions, and is safe and reliable, thereby improving the quality of life of patients. This technique is worthy of further research conducted with a larger sample size, and could be used in clinical practice.

COMMENTS

Background

Chronic ulcerative colitis is common, and has a high incidence. Abdominal pain, tenesmus and sepsis are the main clinical manifestations of this disease, which can decrease the quality of life of patients. Ulcers of the colonic mucosa occur in patients with chronic ulcerative colitis, which can affect the entire colon and rectum, and induce repeated attacks. Sulfasalazine is a commonly used conventional treatment for chronic ulcerative colitis. However, it has certain limitations such as disease recurrence and side effects. Hence, there is a need for better treatment options.

Research frontiers

Although the pathogenesis of chronic ulcerative colitis is unclear, the close relationship between this disease and immune dysfunction has been confirmed. Furthermore, the expression levels of cytokines, particularly interleukin-8, significantly increase during the disease course.

Innovations and breakthroughs

Stellate ganglion block is a very common clinical block technique that has been used since the beginning of the last century. Studies have shown that stellate ganglion block can regulate multiple system functions in the body, and has a good effect on blood pressure, hyperthyroidism, peripheral facial paralysis and other diseases. With the current rapid development of medicine, some scientists have found that the stellate ganglion block technique also plays an important role in regulating the immune system. Thus, we speculate that stellate ganglion blocks may also have a role in the treatment of chronic ulcerative colitis.

Applications

The stellate ganglion block technique can effectively improve the efficacy of chronic ulcerative colitis treatment, relieve clinical symptoms in patients, and reduce the level of inflammatory factors. Furthermore, it has fewer adverse reactions, thereby making it a safe and reliable treatment method.

Peer-review

Stellate ganglion block technique can effective improve the efficiency of chronic ulcerative colitis treatment, relieve the clinical symptoms of patients, and reduce the level of inflammatory factors. Furthermore, it has fewer adverse reactions, thereby allowing it to be a safe and reliable treatment method. This technique is worthy of further studies conducted with large sample sizes, and can be used in clinical practice.
REFERENCES

1. Dugani A, Dakhil B, Treece S. Protective effect of the methanolic extract of malva parviflora l. leaves on acetic acid-induced ulcerative colitis in rats. Saudi J Gastroenterol 2016; 22: 226-233

2. Postovolova EA, Khochansky DN, Zolotova NA, Gao Y, Makarova OV, Dobrynina MT. Morphological Changes in Mesenteric Lymph Nodes and Lymphocyte Subpopulation Composition in Experimental Ulcerative Colitis. Bull Exp Biol Med 2016; 160: 835-839 [PMID: 27165070 DOI: 10.1007/s10517-016-1322-5]

3. Wanderas MH, Moum BA, Heivik ML, Hovde Ø. Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. World J Gastrointest Pharmacol Ther 2016; 7: 235-241 [PMID: 27158539 DOI: 10.4292/wjgpt.v7.i2.235]

4. Nidhi M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J 2016; 24: 458-472 [PMID: 27330377 DOI: 10.1016/j.sparj.2014.10.001]

5. Zhai O, Benfor B, Jiber H, Bouarhroum A. Embolic lower limb ischemia as a rare complication of ulcerative colitis: A case report and literature review. J Mal Vac 2016; 41: 279-285 [PMID: 27324295 DOI: 10.1111/jmv.2016.05.011]

6. Peyrin-Biroulet L, Bouhnik Y, Robin X, Bonnaud G, Hagehe H, Hébuterne X. French national consensus clinical guidelines for the management of ulcerative colitis. Dig Liver Dis 2016; 48: 726-733 [PMID: 27158125 DOI: 10.1016/j.dld.2016.03.029]

7. Scaldaferri F, Gerardi V, Mangioli F, Lopetuso LR, Pizzoferrato M, Petereit DG, Sloan JA, Liu H, Martenson JA, Rasti M, Shirazi Yeganeh B, Niknahad H, Saeedi A, Wang X, Min L, Shen Z, Ruan Y, Qiu J, Sun Y, Qin X. Loss of OLFM4 promotes tumor migration through inducing interleukin-8 expression and predicts lymph node metastasis in early gastric cancer. Oncogenesis 2016; 5: e234 [PMID: 27294866 DOI: 10.1038/oncsis.2016.42]

8. Lin X, Yang C, Huang L, Chen M, Shi J, Ouyang L, Tang T, Zhang W, Li Y, Liang R, Jiang S. Upregulation of TRPM7 augments cell proliferation and interleukin-8 release in airway smooth muscle cells of rats exposed to cigarette smoke. Mol Med Rep 2016; 13: 4995-5004 [PMID: 27108806 DOI: 10.3892/mmr.2016.5161]

9. Keskiner I, Lutfioğlu M, Aydoğdu A, Saygun NL, Serdar MA. Effect of Photobiomodulation on Transforming Growth Factor-β1, Platelet-Derived Growth Factor-BB, and Interleukin-8 Release in Palatal Wounds After Free Gingival Graft Harvesting: A Randomized Clinical Study. Photomed Laser Surg 2016; 34: 263-271 [PMID: 27088277 DOI: 10.1089/pho.2016.4094]

10. Joeng ES, Jeong YC, Park BJ, Kang S, Yang SN, Yoon JS. Sononanatomical Change of Phrenic Nerve According to Posture During Ultrasound-Guided Stellate Ganglion Block. Ann Behab Med 2016; 40: 244-251 [PMID: 27152274 DOI: 10.1007/s00201-016-0445-9]

11. Kim GW, Mun KH, Song JY, Kim BG, Jung JK, Lee CS, Cha YD, Song JH. Seborrhoeic dermatitis treatment with stellate ganglion block: a case report. Korean J Anesthesiol 2016; 69: 171-174 [PMID: 27064785 DOI: 10.1016/j.kjae.2016.09.011]

12. Ghai A, Kaushik T, Kundu ZS, Wadhwa S, Wadhwa R. Evaluation of new approach to ultrasound guided stellate ganglion block. Saudi J Anaesth 2016; 10: 161-167 [PMID: 27051366 DOI: 10.4103/1658-354x.168815]

13. Nie Y, Song R, Chen W, Qin Z, Zhang J, Tang J. Effects of stellate ganglion block on cerebrovascular vasodilation in elderly patients and patients with subarachnoid haemorrhage. Br J Anaesth 2016; 117: 131-132 [PMID: 27317713 DOI: 10.1093/bja/aew157]

14. Hanling SR, Hickey A, Lesnik I, Hackworth RJ, Stedje-Larsen E, Drastal CA, McCay RN. Stellate Ganglion Block for the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind, Controlled Trial. Reg Anesth Pain Med 2016; 41: 494-500 [PMID: 27187898 DOI: 10.1097/AAP.0000000000000402]

15. Lipov E, Ritchie EC. A review of the use of stellate ganglion block in the treatment of PTSD. Curr Psychiatry Rep 2015; 17: 59 [PMID: 26073366 DOI: 10.1007/s11920-015-0599-4]

16. Immani F, Hemati K, Rahimzadeh P, Kazemi MR, Hejazian K. Effectiveness of Stellate Ganglion Block Under Fluoroscopy or Ultrasound Guidance in Upper Extremity CRPS. J Clin Diagn Res 2016; 10: UC09-UC12 [PMID: 26894152 DOI: 10.7860/jcdr/2016/144767.7035]

17. Xavier TV, de Oliveira TR, Mendes TC. Treatment of patients with painful blind eye using stellate ganglion block. Braz J...
Zhao HY et al. Study on new therapy for chronic UC

Toxicol Res 2016; 32: 115-121 [PMID: 27123162 DOI: 10.5487/tr.2016.32.2.115]

Zhang H, Deng A, Zhang Z, Yu Z, Liu Y, Peng S, Wu L, Qin H, Wang W. The protective effect of epicatechin on experimental ulcerative colitis in mice is mediated by increasing antioxidation and by the inhibition of NF-κB pathway. Pharmacol Rep 2016; 68: 514-520 [PMID: 26878122 DOI: 10.1016/j.pharep.2015.12.011]

Mulvaney SW, Lynch JH, de Leeuw J, Schroeder M, Kane S. Neurocognitive Performance is Not Degraded After Stellate Ganglion Block Treatment for Post-Traumatic Stress Disorder: A Case Series. Mil Med 2015; 180: e601-e604 [PMID: 25939118 DOI: 10.7205/milmed-d-14-00504]

Kim J, Park HS, Cho SY, Baik HI, Kim JH. The effect of stellate ganglion block on intractable lymphedema after breast cancer surgery. Korean J Pain 2015; 28: 61-63 [PMID: 25589949 DOI: 10.3344/kjp.2015.28.1.61]

Uchida T, Nakao S, Morimoto M, Iwamoto T. Serious cervical hematoma after stellate ganglion block. J Anesth 2015; 29: 321 [PMID: 25256578 DOI: 10.1007/s00540-014-1914-7]

Kumar N, Thapa D, Gombar S, Ahuja V, Gupta R. Analgesic efficacy of pre-operative stellate ganglion block on postoperative pain relief: a randomised controlled trial. Anaesthesia 2014; 69: 954-660 [PMID: 25040168 DOI: 10.1111/anae.12774]

Pinkerton JV, Wilson CS. Perspectives on the first randomized sham-controlled trial of stellate ganglion block for hot flashes. Menopause 2014; 21: 788-791 [PMID: 24983275 DOI: 10.1097/GME.0000000000000295]

Arai Y, Matsuura T, Matsuura M, Fujisawa M, Okayasu I, Ito S, Arhiro S. Prostaglandin E-Major Urinary Metabolite as a Biomarker for Inflammation in Ulcerative Colitis: Prostaglandins Revisited. Digestion 2016; 93: 32-39 [PMID: 26788915 DOI: 10.1159/000441665]

Shimizu S, Kouzaki H, Kato T, Tojima I, Shimizu T. HMGB1-TLR4 signaling contributes to the secretion of interleukin 6 and interleukin 8 by nasal epithelial cells. Am J Rhinol Allergy 2016; 30: 167-172 [PMID: 27216346 DOI: 10.2500/ajra.2016.30.4300]

Chen YQ, Jin JX, Liu ZF, Zhu MF. Effects of stellate ganglion block on cardiovascular reaction and heart rate variability in elderly patients during anesthesia induction and endotracheal intubation. J Clin Anesth 2015; 27: 140-145 [PMID: 25559299 DOI: 10.1016/j.jclinane.2014.06.012]

Mulvaney SW, Lynch JH, Hickey MJ, Rahman-Rawlins T, Schroeder M, Kane S, Lipov E. Stellate ganglion block used to treat symptoms associated with combat-related post-traumatic stress disorder: a case series of 166 patients. Mil Med 2014; 179: 1133-1140 [PMID: 25260132 DOI: 10.7205/milmed-d-14-00151]

P- Reviewer: Kositamongkol P  S- Editor: Q Y  L- Editor: Webster JR  E- Editor: Liu WX
